- Home page
- Investor Relations
- Press Releases
-
GVS - 2023-2025 Financial Targets ApprovalPrice Sensitive
-
GVS Starts a Share Management Programme to Support Stock Liquidity
-
Notice of Publication of Documentation
-
GVS - Consolidated H1 2023 Results ApprovalPrice Sensitive
-
Notice of publication of documentation
-
Publication of Article of association
-
GVS - Consolidated Q1 2023 Results Approval
-
The Board of Directors appoints Massimo Scagliarini as CEO and establishes Board Committees
-
GVS Shareholders' meeting approves 2022 Financial Statement and the renewal of corporate bodies. Alessandro Nasi appointed Chairman
-
GVS - Amendment of the 2023 Calendar of Corporate Financial Events
-
Press release pursuant to art. 85-bis Issuers Reg_ Notice on total amount of voting rights
-
Notice of publication 12th April 2023
-
Publication of the lists for the appointment of the Board of Directors and the Board of Statutory Auditors
-
GVS - Board of Directors convenes Shareholders' Meeting for Wednesday, May 3rd, 2023Price Sensitive
-
GVS - Consolidated FY 2022 Results ApprovalPrice Sensitive
-
GVS - Subordinated loan by the majority shareholder - amendment of financial covenantPrice Sensitive
-
2023 Calendar Of Corporate Financial Events
-
GVS loses PMI (SME) status
-
GVS_ Disclosure of total amount of voting rights
-
Agreement to amend and adjust the financial covenant (leverage ratio) and commitment of the Shareholder to provide a subordinated shareholder loan
-
GVS Board of Directors approved the consolidated results as at 30 September 2022Price Sensitive
-
Marco Pacini is the new Group CFO of GVSPrice Sensitive
-
Notice: Publication of Documentation
-
The GVS BoD approved the consolidated results as at 30 June 2022Price Sensitive
-
Haemotronic Acquisition closing
-
Notice of pubblication
-
GVS Haemotronic's Acquisition - AUDIO
-
GVS Haemotronic Acquisition Analyst Presentation
-
GVS Acquisition of 100% of the Italian Group Haemotronic - Integration of the Press Release
-
GVS acquires 100% of the Italian Group Haemotronic, leader in the production of components in the medical and pharmaceutical industries for 212 million euroPrice Sensitive
-
The GVS BoD approved the consolidated results as at 31 March 2022
-
GVS Shareholders' Meeting approves 2021 Financial Statements
-
Notice on total amount of voting rights
-
Notice pubblication of documentation
-
The Board of Directors convenes the shareholders' meeting for Thursday 28 April 2022
-
The GVS Board of Directors approved the 2021 consolidated results and the draft financial statements as at 31 December 2021Price Sensitive
-
Acquisition of Shanghai Transfusion Technology Co. Ltd. completed a strategic opportunity for GVS to fully enter the Chinese healthcare market
-
Conclusion of the first part of the treasury shares purchase programPrice Sensitive
-
Share buyback informationPrice Sensitive
-
Share buyback information
-
2022 Corporate Events Calendar
-
Share buyback information
-
3F Buyback Dicember 2021
-
Share buyback information
-
Share buyback information
-
GVS Acquires 100% of the Shanghai Transfusion Technology Co., LTD.Price Sensitive
-
Share buyback information
-
Share buyback information
-
3F Buyback November 2021
-
Share buyback information
-
Share buyback information
-
Share buyback information
-
Notice of Publication of Documents
-
GVS Approves consolidated results to 30 September 2021Price Sensitive
-
Share buyback information
-
3F Buyback October 2021
-
Share buyback information
-
Share buyback information
-
Share buyback information
-
GVS Launches treasury share buyback programmePrice Sensitive
-
GVS Approves consolidated results to 30 June 2021 revenues up 29.7%, EBITDA margin at 37.9%Price Sensitive
-
GVS Acquires 100% of the RPB Group, an American player specialised in the design and production of respiratory protection devices, and completes its product range in the world of professional masksPrice Sensitive
-
GVS Approves consolidated results as at 31 March 2021Price Sensitive
-
The GVS BOD approves the 2020 financial statement: revenues up 60%, strong growth in Group profitability and solid increase in all key economic and financial indicatorsPrice Sensitive
-
2021 Corporate Events CalendarPrice Sensitive
-
GVS Approves the consolidated results at 30 September 2020 revenue up 49.6% and marked growth of the Group’s profit marginPrice Sensitive
-
The BOD of GVS approves the first half 2020 results revenue at 30 June 2020 up 25% and considerable growth in profit marginPrice Sensitive
-
Completion of the Closing of the acquisition of Haemonetics Puerto Rico, LLCPrice Sensitive
-
2020 Corporate Events CalendarPrice Sensitive
-
GVS Announces the agreement to acquire Puerto Rico-based manufacturing operations of Haemonetics
For the dissemination of Regulated Information, GVS SpA has chosen to use the eMarket SDIR system (www.emarketstorage.com), managed by Teleborsa S.r.l with headquarters in Roma, Piazza di Priscilla 4 and authorized by CONSOB.